Taxus Liberté finally reaches US market
This article was originally published in Clinica
Executive Summary
Boston Scientific's second-generation drug-eluting stent (DES), Taxus Liberté, has been approved by the US FDA.
You may also be interested in...
MRM Health Pulls A Pouchitis Hit Out Of The Bag
The mid-stage success is encouraging, but taking on Takeda won’t be easy.
Novartis Draws Out Its APPLAUSE
Another data drop from Fabhalta’s IgAN trial looks encouraging, despite a missing abstract.
Roche Steals A March In B-cell Lymphoma
New data on Columvi could allow the bispecific’s use as an earlier treatment, giving it a three-year head start on AbbVie and Genmab’s Epkinly.